Breaking News Instant updates and real-time market news.

NBY

NovaBay

$3.63

0.1326 (3.79%)

, LAUR

Laureate Education

$13.64

-0.16 (-1.16%)

17:25
03/20/18
03/20
17:25
03/20/18
17:25

On The Fly: After Hours Movers

UP AFTER EARNINGS: NovaBay (NBY), up 9.7%... Laureate Education (LAUR), up 4.9%. ALSO HIGHER: Prothena (PRTA), up 20.5% after it announced a collaboration deal with Celgene (CELG)... Black Box (BBOX), up 4.8% after it was selected for the U.S. Army SWA-OSP engineering and modernization program... MuleSoft (MULE), up 4.8% after it agreed to be acquired by Salesforce (CRM) for $6.5B in cash and stock. DOWN AFTER EARNINGS: FedEx (FDX), down 0.4%. ALSO LOWER: TPG Specialty Lending (TSLX), down 3.6% after it filed to sell 3.75M shares of common stock... DBV Technologies (DBVT), down 3.5% after it filed to sell $150M in common stock... Salesforce, down 2.9% after it agreed to acquire MuleSoft.

NBY

NovaBay

$3.63

0.1326 (3.79%)

LAUR

Laureate Education

$13.64

-0.16 (-1.16%)

PRTA

Prothena

$33.85

0.68 (2.05%)

CELG

Celgene

$88.27

-0.26 (-0.29%)

BBOX

Black Box

$2.10

0.05 (2.44%)

MULE

MuleSoft

$42.00

8.97 (27.16%)

CRM

Salesforce

$125.12

0.14 (0.11%)

FDX

FedEx

$251.99

2.38 (0.95%)

TSLX

TPG Specialty Lending

$17.90

-0.03 (-0.17%)

DBVT

DBV Technologies

$22.01

-0.6 (-2.65%)

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 23

    Mar

  • 25

    Mar

  • 30

    May

  • 21

    Mar

  • 21

    Mar

NBY NovaBay
$3.63

0.1326 (3.79%)

03/28/17
LDLW
03/28/17
INITIATION
Target $10
LDLW
Buy
NovaBay initiated with a Buy at Laidlaw
Laidlaw analyst Jim Molloy initiated NovaBay with a Buy and a $10 price target saying it represents an exciting turnaround story since their new CEO Mark Sieczkarek transformed their commercial strategy at the beginning of 2016 from a buy and bill sales model to focusing on prescription sales through ophthalmologists. While NovaBay is solely focusing on U.S. Avenova sales for the moment, the approximately $30M recurring patients with blepharitis and dry eye alone attests to the impressive size of the market opportunity, the analyst wrote.
06/05/17
ROTH
06/05/17
INITIATION
Target $5.5
ROTH
Buy
NovaBay initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry initiated NovaBay with a Buy rating and $5.50 price target.
LAUR Laureate Education
$13.64

-0.16 (-1.16%)

11/16/17
MSCO
11/16/17
NO CHANGE
Target $18
MSCO
Overweight
Laureate discount to IPO level a buying opportunity, says Morgan Stanley
Morgan Stanley analyst Javier Martinez de Olcoz Cerdan noted that Laureate Education has soldoff 17% since its Q3 report, but he sees four factors - sequential volume growth, accretive asset sales, pro-market elections in Chile and profitability - as possibly driving a re-rating in the stock and pushing it back to its IPO level of $14 or higher. With volume growth, asset sales and Chile's political situation on track, a clear management commitment to improve profitability will be the key, said the analyst, who keeps an Overweight rating and $18 price target on Laureate shares.
12/28/17
BARD
12/28/17
NO CHANGE
Target $16
BARD
Outperform
Laureate Education valuation compelling at current levels, says Baird
Baird analyst Jeffrey Meuler noted Laureate Education announced its fourth divestiture since late November as part of its plans to divest five to seven locations. He believes its current valuation remains compelling as the divestitures are being done at attractive multiples well above their public market value. Meuler sees an improving risk/reward profile and reiterated his Outperform rating and $16 price target on Laureate Education shares.
12/19/17
STFL
12/19/17
NO CHANGE
Target $18
STFL
Buy
Chilean election result a material positive for Laureate Education, says Stifel
Stifel analyst Shlomo Rosenbaum said Chile's election result is a "material positive" for Laureate Education as Sebastian Pinera is less likely to support legislation for free post-secondary education, the prospect of which has weighed on the stock. He maintains a Buy rating and $18 price target on Laureate shares.
11/24/17
BARD
11/24/17
NO CHANGE
Target $16
BARD
Outperform
Laureate received 'attractive' multiple in EU asset sales, says Baird
Baird analyst Jeffrey Meuler said he was incrementally positive on Laureate Education after the company announced the sale of its Italian and Cyprus universities at a substantial premium to the current Laureate multiple and substantially higher than he would have expected. The analyst, who continues to view Laureate's valuation as attractive, keeps an Outperform rating on the shares.
PRTA Prothena
$33.85

0.68 (2.05%)

02/05/18
CANT
02/05/18
NO CHANGE
Target $65
CANT
Overweight
Prothena data release could assuage concerns, says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner cautions against "over-interpreting" the resignation of Prothena's Chief Medical Officer given the lack of details. The release of top-line data from the Phase 2b Pronto study has the ability to "clear the air" and assuage investor concerns, Tanner tells investors in a research note titled "PRONTO Trial Data Could Go A Long Way Toward Disproving A Negative." The analyst keeps an Overweight rating on the shares with a $65 price target.
02/05/18
NOMU
02/05/18
NO CHANGE
Target $87
NOMU
Buy
Prothena selloff on CMO resignation brings entry point, says Nomura Instinet
Nomura Instinet analyst Christopher Marai recommends using the weakness in shares of Prothena following the resignation of Chief Medical Officer Sarah Noonberg as a buying opportunity. The analyst keeps a Buy rating on the shares with an $87 price target.
12/21/17
CANT
12/21/17
NO CHANGE
Target $65
CANT
Overweight
Prothena price target lowered to $65 from $80 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Prothena to $65 after the company guided to the last event in the VITAL Phase 3 study likely occurring in the second half of 2019 versus the latter part of 2018 as previously expected. The analyst, however, believes the delay does little to change the long-term investment thesis. He keeps an Overweight rating on Prothena.
11/20/17
11/20/17
DOWNGRADE
Target $55

Neutral
Prothena downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst David Nierengarten downgraded Prothena to Neutral from Outperform as it is not clear to him that the one-year delay in VITAL unblinding to 2H19 could be due solely to NEOD001 benefit. With his Prothena valuation based almost entirely on NEOD001 success, the analyst sees risk/reward as now skewed to downside. Nierengarten also lowered his price target on the shares to $55 from $75.
CELG Celgene
$88.27

-0.26 (-0.29%)

03/14/18
RBCM
03/14/18
NO CHANGE
Target $131
RBCM
Top Pick
Celgene has valuation floor from possibility of going private, says RBC Capital
RBC Capital analyst Brian Abrahams writes that Celgene's strong near-term cash flows and drug pipeline are overshadowed by the "Revlimid goes generic" cliff in the next 4-7 years. Abrahams speculates that a transaction taking Celgene private offers "upside for current shareholders, insulation vs. medium-term volatility (during) transition to a post-Revlimid business model, and appreciation for a buyer". While the deal is not likely, the analyst contends that its economics imply a valuation floor on the stock, keeping his Top Pick rating and $131 price target on Celgene.
02/28/18
02/28/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Celgene (CELG) downgraded to Hold from Buy at SunTrust by analyst Yatin Suneja after the company received a refusal to file letter from the FDA on ozanimod for relapsing forms of multiple sclerosis. Suneja said that following pipeline setbacks in late 2017, ozanimod was central to his "bull thesis to re-accelerate growth" and provide "much needed diversification away from myeloma." Given the delay, he lowered his ozanimod peak sales estimate to $3.5B from $5B. The refusal to file letter could result in a 24-month or longer delay for ozanimod's launch in relapsing forms of multiple sclerosis, Suneja said. 2. Frontier Communications (FTR) downgraded to Hold from Buy at Jefferies by analyst Scott Goldman. With the dividend now suspended and EBITDA stabilization "still a work in progress," the shares have no near-term catalyst, Goldman said. He believes "significant challenges" remain for Frontier following the dividend suspension. 3. Comcast (CMCSA, CMCSK) downgraded to Neutral from Outperform at Macquarie by analyst Amy Young, who cited uncertainty around the M&A playbook and increased net leverage. Young said Comcast's intention to acquire Sky (SKYAY) diversifies its portfolio and increases international revenues to 25% of total from 9% currently, but exposes it to satellite TV, which faces secular pressures. The analyst views the 12x price tag for Sky as high, questions the synergies, and believes the unpredictability could cap near-term upside. 4. e.l.f. Beauty (ELF) downgraded to Market Perform from Outperform at BMO Capital by analyst Shannon Coyne, who cited the "near-term challenges in the mass category" and heightened competition yielding further pressure on results and the stock in the near term. The analyst also points to the management having lowered its expectations for the 3rd time in 6 months, adding that it may take some time for investor confidence to return. Despite the downgrade, the analyst believes that e.l.f "has material white space in existing and new retailers" as well as an "unmatched strong value proposition." 5. Maxim Integrated (MXIM) downgraded to Neutral from Outperform at Macquarie by analyst Srini Pajjuri, who said shares have significantly outperformed the SOX index year-to-date and believes healthy fundamentals are now backed in, combined with some M&A premium. Pajjuri believes further upside is limited on a fundamental basis and believes comps will get tougher in the second half of 2018 and sees risk of higher volatility in Consumer as Samsung GS9 builds fade. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/28/18
UBSW
02/28/18
NO CHANGE
Target $106
UBSW
Buy
Celgene NDA application denial raises execution questions, says UBS
UBS analyst Carter Gould noted Celgene disclosed the FDA issued a Refusal to File regarding the NDA for ozanimod in multiple sclerosis. He believes this will likely delay its approval until at least 2019 and raise another round of questions on Celgene's execution as the last six months have brought clinical, regulatory, and commercial setbacks. Gould maintained his Buy rating, but lowered his price target to $106 from $120 on Celgene shares.
03/20/18
PIPR
03/20/18
NO CHANGE
Target $95
PIPR
Neutral
Arena data looks competitive to Celgene's ozanimod, says Piper Jaffray
Last night's data from Arena Pharmaceuticals' (ARNA) competitor to Celgene's (CELG) ozanimod looks at least comparable to if not slightly advantageous versus ozanimod in previously treated ulcerative colitis, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Ozanimod's Competitive Outlook Just a Little Bit Less Clear With New ARNA Data." The analyst says that while there is "no perfect apples to apples comparison," Arena's etrasimod, at the very least, is competitive with ozanimod. He prefers to remain on the sidelines with respect to Celgene shares, noting consensus still models "sizeable uptake" for ozanimod. Raymond has a Neutral rating on Celgene with a $95 price target.
BBOX Black Box
$2.10

0.05 (2.44%)

08/11/17
SIDC
08/11/17
DOWNGRADE
Target $7
SIDC
Neutral
Black Box downgraded to Neutral from Buy at Sidoti
Sidoti analyst Gregory Burns downgraded Black Box to Neutral and cut its price target to $7 from $10 following the Q1 miss and dividend elimination, and said the business took another "step down."
06/27/17
SIDC
06/27/17
UPGRADE
Target $10
SIDC
Buy
Black Box upgraded to Buy from Neutral at Sidoti
Sidoti upgraded Black Box to Buy citing valuation and maintained a $10 price target on shares.
06/27/17
06/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. EOG Resources (EOG) was upgraded to Overweight from Neutral by Atlantic Equities analyst Barry MacCarthy, who calls it one of the best placed E&P companies to manage at current oil prices given its peer-leading Permian performance and falling costs across many areas. 2. Cabot Microelectronics (CCMP) was upgraded to Buy from Hold by Needham analyst Y. Edwin Mok, citing its high exposure to strong growth in 3D NAND production and the increased success of its pad business. 3. Bemis (BMS) was upgraded to Overweight from Equal Weight by Barclays analyst Scott Gaffner, who contends that the company's shift from transformation to a self-funded turnaround brings the potential for "meaningful" share upside. 4. Pier 1 Imports (PIR) was upgraded to Hold from Reduce at Gordon Haskett, whose analyst thinks the shares could be a short squeeze candidate. 5. Black Box (BBOX) was upgraded to Buy from Neutral at Sidoti, citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MULE MuleSoft
$42.00

8.97 (27.16%)

02/16/18
JPMS
02/16/18
UPGRADE
Target $35
JPMS
Overweight
JPMorgan sees path to $1B in revenue, upgrades MuleSoft to Overweight
JPMorgan analyst Mark Murphy upgraded MuleSoft to Overweight from Neutral and raised his price target for the shares to $35 from $27. The company's vision to reach $1B in revenue by 2021 is "achievable absent a recession in the next two years," Murphy tells investors in a post-earnings research note. He adds that his fieldwork suggests "continued strong pipeline and a growing opportunity set for MuleSoft." The analyst believes the company's headwinds are fading and catalysts are emerging
03/06/18
OPCO
03/06/18
NO CHANGE
Target $38
OPCO
Outperform
MuleSoft price target raised to $38 from $32 at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target for MuleSoft to $38 from $32 after meeting with management as he came away with increased confidence in the company's TAM, its ability to gain share, its competitive positioning. The analyst reiterates an Outperform rating on the shares.
02/16/18
PIPR
02/16/18
NO CHANGE
Target $33
PIPR
Overweight
MuleSoft price target raised to $33 from $28 at Piper Jaffray
Piper Jaffray analyst Alex Zukin raised his price target for MuleSoft to $33 saying the company posted a "very strong" end to the year, highlighted by 50% billings growth. The analyst believes MuleSoft could see "significant" free cash flow leverage. He reiterates an Overweight rating on the shares.
02/16/18
JPMS
02/16/18
UPGRADE
JPMS
Overweight
MuleSoft upgraded to Overweight from Neutral at JPMorgan
CRM Salesforce
$125.12

0.14 (0.11%)

03/20/18
STFL
03/20/18
DOWNGRADE
Target $53
STFL
Hold
Stifel finds Oracle results 'concerning,' downgrades shares to Hold
Stifel analyst Brad Reback downgraded Oracle (ORCL) to Hold from Buy following last night's Q3 earnings report. The company's sales results were again "mixed" with cloud revenue near the lower end of constant currency guidance, Reback tells investors in a research note partially titled "Where's The Beef?" He notes Oracle's Q4 cloud and total revenue guidance missed consensus expectations. The analyst finds the results and outlook "concerning," especially when considering the strong results posted by peers like Microsoft (MSFT), Salesforce (CRM) and Adobe (ADBE). Reback has a $53 price target for Oracle shares. The stock in premarket trading is down 8% to $47.70.
03/16/18
BMOC
03/16/18
NO CHANGE
Target $260
BMOC
Outperform
Adobe price target raised to $260 from $205 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Adobe (ADBE) to $260 after its Q1 earnings beat, saying the company's free cash flow generation growth and valuation warrant for the stock to retain his Top Pick designation. The analyst states that both operating margin expansion and free cash flows were "impressive", while the company's outlook is also likely to prove to be conservative. Bachman keeps his Outperform rating on Adobe, adding that the company has potential for new market opportunities such as cloud services and also offers more margin upside and relative value next to similarly-rated salesforce.com (CRM).
03/20/18
JMPS
03/20/18
NO CHANGE
Target $126
JMPS
Outperform
Salesforce comp plan should help motivate Q1 performance, says JMP Securities
JMP Securities analyst Patrick Walravens noted two "interesting data points" about Salesforce (CRM) he came across while conducting his due diligence on Oracle's (ORCL) quarter. Namely, he heard that Salesforce's sales compensation plan includes a bonus for deals closed by April 15, which he thinks should help motivate the sales force toward hitting targets early in Q1. Also, he understands that Brian Millham, previously President of Global Commercial Sales and then SVP of Corporate Sales, is apparently on sabbatical and Warren Wick, who was previously SVP of Enterprise Sales, was promoted to EVP in February to run the commercial business. Walravens maintains his Outperform rating and $126 price target on Salesforce shares.
03/02/18
ARGS
03/02/18
NO CHANGE
Target $141
ARGS
Buy
Salesforce price target raised to $141 from $130 at Argus
Argus analyst Joseph Bonner raised his price target on Salesforce to $141 and kept his Buy rating following the company's "strong" Q4 earnings report and raised FY19 guidance. Bonner states that Salesforce is operating with momentum and remains well positioned to take advantage of "secular trends toward software-as-a-service cloud solutions, data analytics, and platform software services". The analyst adds that Salesforce is successfully gaining market share as it continues to innovate in enterprise cloud CRM space.
FDX FedEx
$251.99

2.38 (0.95%)

03/13/18
SBSH
03/13/18
NO CHANGE
Target $304
SBSH
Buy
FedEx stock 'lull' brings buying opportunity, says Citi
Citi analyst Christian Wetherbee believes the "lull" in FedEx shares presents a buying opportunity ahead of June. The analyst, however, lowered his Q3 earnings per share estimate to $3.10 from $3.30 to reflect "some challenging" January weather. FedEx will provide two positive messages in June, Wetherbee tells investors in a research note. The first being Ground capex declining and the second will be above consensus fiscal 2019 guidance, the analyst contends. He sees "material upside potential" in FedEx shares and keeps a Buy rating on the name with a $304 price target.
02/28/18
WELS
02/28/18
NO CHANGE
WELS
Amazon delivery pilot program not incremental development, says Wells Fargo
Wells Fargo analyst Matthew Troy notes that Amazon (AMZN) announced the launching of a pilot program to pick-up and deliver packages in Los Angeles. The analyst does not view Shipping with Amazon as an incremental development in the e-Commerce giant's strategy or a change in the competitive risk dynamic for either UPS (UPS) or FedEx (FDX). Troy highlights that Amazon already offers a similar service in London, and is already delivering packages in nearly 40 U.S. cities. He still believes it would cost Amazon between $50B-$100B to build out a global network with sufficient reach and scale to compete directly with FedEx and UPS.
03/16/18
OPCO
03/16/18
NO CHANGE
Target $274
OPCO
Outperform
FedEx price target raised to $274 at Oppenheimer ahead of Q3 earnings report
Oppenheimer analyst Scott Schneeberger raised his price target on FedEx to $274 from $265 and reiterated his Outperform rating on shares ahead of the company's Q3 earnings release on March 20. In a research note to investors, the analyst said FedEx appears to have executed well during 2017's peak season, delivering "strong" service levels as it seemingly achieved its operational and financial goals. Schneeberger anticipates continued segment margin expansion in Ground, and noted that the business environment for Express and Freight has been "favorable" considering strong international air freight and Less Than Truckload market conditions. The analyst also said he is "incrementally conservative" on FedEx's overall operating environment and execution.
02/23/18
02/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FedEx (FDX) upgraded to Outperform from Market Perform at Bernstein with analyst David Vernon saying he expects revenue and earnings growth to be driven by a strengthening global economy and rising interest rates, the tightening domestic transportation market and demand for B2C delivery. 2. BT Group (BT) upgraded to Buy from Hold at Berenberg. 3. Financial Engines (FNGN) upgraded to Outperform from Market Perform at William Blair with analyst Robert Napoli citing the company's "strong" quarter. 4. Lennar (LEN) upgraded to Outperform from In Line at Evercore ISI. 5. Devon Energy (DVN) upgraded to Buy from Hold at KLR Group with analyst John Gerdes noting that the stock is down over 30% and has significantly underperformed the sector since late January, when he had previously downgraded it. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TSLX TPG Specialty Lending
$17.90

-0.03 (-0.17%)

02/26/18
NATL
02/26/18
UPGRADE
NATL
Buy
TPG Specialty Lending upgraded to Buy from Neutral at National Securities
02/22/18
LTCO
02/22/18
UPGRADE
LTCO
Buy
TPG Specialty Lending upgraded to Buy from Neutral at Ladenburg
DBVT DBV Technologies
$22.01

-0.6 (-2.65%)

02/27/18
JMPS
02/27/18
NO CHANGE
Target $30
JMPS
Outperform
JMP waits for greater conviction before upping odds of Viaskin Milk's success
JMP Securities analyst Liisa Bayko said Phase 2 data for DBV Technologies' Viaskin Milk for cow's milk protein allergy showed a robust response in children at the mid-dose. However, it dropped off at higher doses and in adolescents and she would be more confident if a dose-response relationship had been seen, she tells investors. Bayko, who said she prefers to wait to gain greater conviction before increasing her 20% probability of success for Viaskin Milk, maintains her Outperform rating and $30 price target on DBV Technologies shares.
03/15/18
HCWC
03/15/18
NO CHANGE
Target $50
HCWC
Buy
H.C. Wainwright sees 'several points' in favor of approval for DBV
With DBV Technologies preparing its Biologics License Application for Viaskin Peanut to be filed in the second half of 2018, H.C. Wainwright analyst Andrew Fein is "eager to see the regulators response." He expects the FDA will be swayed by "several points" in favor of DBVT, including the "very low risk" associated with the Viaskin program due to its "excellent safety and tolerability profile," the treatment appearing to generate a level of efficacy that is sufficient to avoid accidental exposure, and the data suggesting that the longer a patient is on the patch, the greater the level of tolerance developed and the greater the likelihood that patients could achieve the minimal threshold for protection. Fein reiterates a Buy rating on DBV shares with a $50 price target.
03/05/18
HCWC
03/05/18
NO CHANGE
HCWC
Buy
H.C. Wainwright positive on DBV after attending AAAAI Conference
H.C. Wainwright analyst Andrew Fein spent time with "leading" key opinion leaders in food allergy at this year's American Academy of Allergy, Asthma and Immunology meeting to talk about the oral immunotherapy from Aimmune Therapeutics (AIMT) and epicutaneous immunotherapy from DBV Technologies (DBVT). Although there were positives viewed from both approaches, the KOLs believe that the stronger safety profile along with the convenience of the patch will generate more support for DBV from parents who wish to ensure that their children are not at risk of a life-threatening situation due to an accidental exposure to peanut protein, Fein tells investors in a research note. The analyst believes DBV's ViaSkin peanut patch provides a safe and effective means to increase peanut tolerance. He sees "very low risk" associated with the DBV program due to its "excellent" safety and tolerability profile. Secondly, it appears to generate at a level of efficacy that is sufficient to avoid accidental exposure, Fein tells investors. He adds the company appears to be in the enviable position of submitting its approval application to the FDA before Aimmune. Fein has a Buy rating on DVT and does not rate Aimmune.
03/06/18
DBAB
03/06/18
NO CHANGE
Target $30
DBAB
Buy
Deutsche Bank 'increasingly bullish' on DBV's Viaskin Peanut
Deutsche Bank analyst Andrew Peters is "increasingly bullish" on DBV Technologies' (DBVT) Viaskin Peanut following conversations with allergy practitioners at this year's American Academy of Allergy, Asthma & Immunology meeting. Feedback from expert checks and conversations at the conference are "highly supportive" of the Viaskin Peanut profile, and "sharply contrasted" to the implied clinical and commercial risk at the current stock price, Peters tells investors in a research note. Physicians view both Viaskin Peanut and Aimmune's (AIMT) AR101 as potentially important options for patients, the analyst adds. Peters reiterates a Buy rating on DBV Technologies with a $30 price target.

TODAY'S FREE FLY STORIES

11:30
08/17/18
08/17
11:30
08/17/18
11:30
Options
Continued interest in PHLX Gold and Silver Mining Index puts »

Continued interest in…

CGC

Canopy Growth

$32.74

1.86 (6.02%)

11:25
08/17/18
08/17
11:25
08/17/18
11:25
Options
Canopy Growth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$33.21

0.13 (0.39%)

, VIA

Viacom

$35.75

0.25 (0.70%)

11:19
08/17/18
08/17
11:19
08/17/18
11:19
Hot Stocks
Box Office Battle: 'Crazy Rich Asians' expected to edge out 'The Meg' »

The major release opening…

T

AT&T

$33.21

0.13 (0.39%)

VIA

Viacom

$35.75

0.25 (0.70%)

VIAB

Viacom

$30.60

0.5 (1.66%)

CMCSA

Comcast

$35.59

-0.07 (-0.20%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$44.86

-0.25 (-0.55%)

FOXA

21st Century Fox

$45.41

-0.3 (-0.66%)

LGF.A

Lionsgate

$22.90

-0.16 (-0.69%)

LGF.B

Lionsgate

$21.71

-0.24 (-1.09%)

SNE

Sony

$54.21

0.385 (0.72%)

DIS

Disney

$112.10

-0.39 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

  • 11

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
08/17/18
08/17
11:17
08/17/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
08/17/18
08/17
11:16
08/17/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
08/17/18
08/17
11:15
08/17/18
11:15
General news
Treasury Option Action: put butterfly positioning in the belly »

Treasury Option Action:…

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

11:13
08/17/18
08/17
11:13
08/17/18
11:13
Hot Stocks
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

TSM

TSMC

$39.87

-0.55 (-1.36%)

NVDA

Nvidia

$247.00

-10.57 (-4.10%)

AMD

AMD

$19.48

0.14 (0.72%)

OSTK

Overstock.com

$30.75

0.55 (1.82%)

DPW

DPW Holdings

$0.42

0.019 (4.76%)

KODK

Kodak

$2.90

-0.1 (-3.33%)

SSC

Seven Stars Cloud Group

$1.99

0.01 (0.51%)

RIOT

Riot Blockchain

$5.35

-0.055 (-1.02%)

TEUM

Pareteum

$2.52

-0.01 (-0.40%)

SRAX

Social Reality

$4.18

-0.16 (-3.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 28

    Aug

  • 12

    Sep

11:05
08/17/18
08/17
11:05
08/17/18
11:05
General news
The U.S. QSS figures »

The U.S. QSS figures that…

NVDA

Nvidia

$247.12

-10.45 (-4.06%)

, ESPR

Esperion

$48.10

1.41 (3.02%)

11:04
08/17/18
08/17
11:04
08/17/18
11:04
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

NVDA

Nvidia

$247.12

-10.45 (-4.06%)

ESPR

Esperion

$48.10

1.41 (3.02%)

DSW

DSW

$25.85

-1.97 (-7.08%)

MTCH

Match Group

$46.87

0.49 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 12

    Sep

  • 12

    Sep

FIBK

First Interstate

$45.20

(0.00%)

11:02
08/17/18
08/17
11:02
08/17/18
11:02
Hot Stocks
First Interstate completes acquisition of Northwest Bancorporation »

Effective August 16,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

LB

L Brands

$32.34

0.24 (0.75%)

11:00
08/17/18
08/17
11:00
08/17/18
11:00
Options
Defensive one-week option play in L Brands ahead of earnings »

Defensive one-week option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

SYMC

Symantec

$19.44

0.115 (0.60%)

10:40
08/17/18
08/17
10:40
08/17/18
10:40
Options
Symantec sees in the money put buying »

Symantec sees in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

DE

Deere

$136.75

-0.63 (-0.46%)

10:39
08/17/18
08/17
10:39
08/17/18
10:39
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere says cash use…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

TSLA

Tesla

$313.73

-21.73 (-6.48%)

10:37
08/17/18
08/17
10:37
08/17/18
10:37
Technical Analysis
Technical Take: Tesla nearing bearish head and shoulders target »

In a note published here…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PK

Park Hotels & Resorts

$32.15

-0.19 (-0.59%)

10:36
08/17/18
08/17
10:36
08/17/18
10:36
Hot Stocks
Park Hotels & Resorts mentioned positively by Hedgeye »

Hedgeye made positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:35
08/17/18
08/17
10:35
08/17/18
10:35
General news
FX Action: Cable is set to rack up a sixth consecutive week of declines »

FX Action: Cable is set…

WBK

Westpac Banking

$21.99

0.09 (0.41%)

10:33
08/17/18
08/17
10:33
08/17/18
10:33
Downgrade
Westpac Banking rating change  »

Westpac Banking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

DE

Deere

$137.29

-0.09 (-0.07%)

10:31
08/17/18
08/17
10:31
08/17/18
10:31
Hot Stocks
Deere expects FY18 net operating cash flows from equipment operations $3.5B »

Says had another…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

SPY

SPDR S&P 500 ETF Trust

$283.54

-0.55 (-0.19%)

10:30
08/17/18
08/17
10:30
08/17/18
10:30
Options
Bullish end of year play in SPYders »

Bullish end of year play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
08/17/18
08/17
10:25
08/17/18
10:25
General news
The Michigan sentiment drop to an 11-month low »

The Michigan sentiment…

GERN

Geron

$3.99

0.04 (1.01%)

10:20
08/17/18
08/17
10:20
08/17/18
10:20
Options
Geron draws far upside call buyers »

Geron draws far upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

10:20
08/17/18
08/17
10:20
08/17/18
10:20
General news
U.S. leading indicator rose 0.6% to 110.7 in July »

U.S. leading indicator…

DARE

Dare Bioscience

$1.01

0.01 (1.00%)

, WSC

WillScot

$16.10

0.2 (1.26%)

10:18
08/17/18
08/17
10:18
08/17/18
10:18
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

DARE

Dare Bioscience

$1.01

0.01 (1.00%)

WSC

WillScot

$16.10

0.2 (1.26%)

LGND

Ligand

$237.18

-2.66 (-1.11%)

COT

Cott Corp.

$15.98

0.34 (2.17%)

AZRE

Azure Power

$15.95

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

DF

Dean Foods

$8.01

-0.62 (-7.18%)

, WAB

Wabtec

$108.87

-1.73 (-1.56%)

10:17
08/17/18
08/17
10:17
08/17/18
10:17
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

DF

Dean Foods

$8.01

-0.62 (-7.18%)

WAB

Wabtec

$108.87

-1.73 (-1.56%)

YUMC

Yum China

$34.48

-0.85 (-2.41%)

DSW

DSW

$25.77

-2.05 (-7.37%)

SUI

Sun Communities

$101.22

-0.895 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 10

    Sep

  • 12

    Sep

  • 06

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
08/17/18
08/17
10:17
08/17/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.